Bright Minds Biosciences EBIT

Bright Minds Biosciences (DRUG) currently reports a EBIT of $-26M as of March 2026. That compares with $-5.5M in the prior-year period — down 374.5% year over year. That is below the Healthcare sector average of $23B. Use the charts on this page to explore Bright Minds Biosciences's EBIT history and peer comparisons.

Bright Minds Biosciences's EBIT decreased from $-5.5M to $-26M — a 374.5% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Bright Minds Biosciences's EBIT of $-26M is lower than the Healthcare sector average of $23B. That is roughly 100.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Bright Minds Biosciences reported $-26M in EBIT as of March 2026. That compares with $-5.5M in the prior-year period — down 374.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-26M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $23B. From there, open related valuation or income-statement pages for Bright Minds Biosciences, and consider following DRUG for alerts when major investors trade the stock.